Maria A. De Ioris
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications
Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression.
Journal: Translational oncology
Published: May 18, 2026
CD19 antigen: from tumor target to safety switch in CAR-T cell therapy.
Journal: Haematologica
Published: April 07, 2026
Long-Term Thyroid Toxicity Burden in Children Who Received Treatment for High-Risk Neuroblastoma.
Journal: Thyroid : official journal of the American Thyroid Association
Published: February 24, 2026
Pediatric high-grade gliomas and cancer predisposition syndromes: A retrospective study.
Journal: HGG advances
Published: December 18, 2025
Mapping B cells and the immune landscape of tertiary lymphoid structures reveals their clinical impact in neuroblastoma.
Journal: Journal for immunotherapy of cancer
Published: October 21, 2025
Liver-Related Late Effects in Long-Term Survivors of High-Risk Neuroblastoma: Insights From a Comprehensive Prospective Follow-Up Study.
Journal: Pediatric blood & cancer
Published: September 16, 2025
Long-term sequelae in survivors of high-risk neuroblastoma: the price of success.
Journal: The Lancet. Child & adolescent health
Published: September 14, 2025
Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: September 09, 2025
Preoperative Cytopenia in Patients Affected by High-Risk Neuroblastoma: Just a Matter of Platelets?
Journal: Pediatric blood & cancer
Published: July 13, 2025
Eye Salvage and Vision Preservation in High-Risk Intraocular Retinoblastoma Patients: Long-Term Results From the Prospective Phase II AIEOP RTB 012 Study.
Journal: Cancer medicine
Published: June 22, 2025
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: March 01, 2025
Last Updated: 09/26/2026